Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
1.
Cardiovasc Intervent Radiol ; 47(6): 795-800, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38438685

RESUMEN

PURPOSE: To assess the technical success, safety and early efficacy of Morton neuroma (MN) cryoneurolysis. MATERIALS AND METHODS: Retrospective review of 54 consecutive patients with MN treated with cryoneurolysis after failure of conservative treatment, from September 2022 to June 2023. Outcomes measurements included technical success (defined a successful ultrasound-guided placement of the cryoprobe), procedural safety according to Cirse classification and change in 6 months post-procedure by pain numeric rating scale (pNRS). RESULTS: A total of 59 MN were treated during 55 procedures. Mean procedure duration was 47 min, all patients were discharged 2 h after the intervention. Technical success was 98.1%. No Cirse grade 3, 4 or 5 complication was reported. Three grade 2 complication occurred, including two chilblain-type lesions and one bone insufficiency fracture. At 6 months post-procedure, pNRS score was significantly decreased (2.7 ± 2.2 vs 7.1 ± 1.1) (p < 0.0001), with a mean score decrease of 4.1points. Thirty-two patients (60.4%) reported a complete pain relief, 15 (28.3%) a partial pain relief and 6 (11.3%) no pain relief, or increased pain. CONCLUSION: Cryoneurolysis seems to be safe for the treatment of Morton neuroma. Six-month pain relief is promising and needs to be confirmed at long term.


Asunto(s)
Criocirugía , Neuroma de Morton , Ultrasonografía Intervencional , Humanos , Femenino , Masculino , Estudios Retrospectivos , Persona de Mediana Edad , Ultrasonografía Intervencional/métodos , Criocirugía/métodos , Criocirugía/efectos adversos , Adulto , Neuroma de Morton/terapia , Neuroma de Morton/cirugía , Neuroma de Morton/diagnóstico por imagen , Anciano , Resultado del Tratamiento , Dimensión del Dolor
2.
J Pers Med ; 13(1)2022 Dec 29.
Artículo en Inglés | MEDLINE | ID: mdl-36675748

RESUMEN

Prostatic artery embolization (PAE) consists of blocking the arteries supplying the prostate to treat benign prostate hypertrophia (BPH). Its effectiveness on both urinary symptoms and flowmetric parameters has now been amply demonstrated by around a hundred studies, including several randomized trials. The main advantage of this procedure is the very low rate of urinary and sexual sequelae, including ejaculatory, with an excellent tolerance profile. The arterial anatomy is a key element for the realization of PAE. Its knowledge makes it possible to anticipate obstacles and prevent potential complications related to nontarget embolization. Nontarget embolization can occur with a small intraprostatic shunt or reflux and has no consequences except some local inflammation symptoms that resolve in a couple of days. Nevertheless, some situations with large arterial shunts arising from the prostatic artery must be recognized (accessory rectal, bladder, or pudendal branches), and must imperatively be protected before embolization, at the risk of exposing oneself to otherwise ischemic complications that are more severe, such as bladder necrosis and skin or mucosal necrosis. This article offers a step-by-step review of the various anatomical and technical key points to ensure technical and clinical success, while avoiding the occurrence of adverse events.

3.
Rheumatology (Oxford) ; 56(6): 947-956, 2017 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-28339663

RESUMEN

Objectives: Specific cardiac involvement in granulomatosis with polyangiitis (GPA) is probably underestimated since many of these conditions are subclinical. The objective of this study was to assess the prevalence and patterns of cardiac abnormalities detected by cardiac MRI (CMRI) in patients with GPA. Methods: Thirty-one consecutive patients with newly diagnosed or relapsing GPA underwent CMRI to assess morphological, functional, perfusion at rest and delayed enhancement abnormalities. Results: At least one abnormality was observed on CMRI for 19 of 31 patients (61%). Four patients (13%) had an impaired left ventricle ejection fraction (LVEF). LV regional wall motion abnormalities were found in 11 patients (35%). Late gadolinium enhancement (LGE) was detected in 10 of 31 patients (32%). LGE was mostly nodular ( n = 9). Myocardial early contrast enhancement was detected in 5 of the 31 patients (16%), which was systematically associated with LGE in the same territory. CMRI detected pericarditis in eight patients (26%). GPA with <18 months duration was associated with a higher LVEF ( P = 0.03), fewer CMRI abnormalities ( P = 0.04) and less LV hypokinesia ( P = 0.04) than GPA with a longer duration. Patients with recent-onset GPA had a higher LVEF ( P = 0.01) and less LV hypokinesia ( P = 0.006) than patients experiencing a relapse ( P = 0.02). Conclusion: CMR is an accurate technique for detecting heart involvement in GPA. This unique non-invasive technique may provide information with important clinical implications for the accurate early assessment of cardiac lesions in GPA patients and for detecting cumulative, irreversible damage. It may also have prognostic implications.


Asunto(s)
Cardiomiopatías/diagnóstico , Granulomatosis con Poliangitis/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Ecocardiografía , Femenino , Humanos , Angiografía por Resonancia Magnética , Imagen por Resonancia Cinemagnética , Masculino , Persona de Mediana Edad , Pericarditis/diagnóstico , Recurrencia , Estudios Retrospectivos , Factores de Riesgo , Disfunción Ventricular Izquierda/diagnóstico , Adulto Joven
4.
Eur Radiol ; 27(2): 821-830, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27271922

RESUMEN

OBJECTIVES: To demonstrate non-inferiority of iobitridol 350 for coronary CT angiography (CTA) compared to higher iodine content contrast media regarding rate of patients evaluable for the presence of coronary artery stenoses. METHODS: In this multicentre trial, 452 patients were randomized to receive iobitridol 350, iopromide 370 or iomeprol 400 and underwent coronary CTA using CT systems with 64-detector rows or more. Two core lab readers assessed 18 coronary segments per patient regarding image quality (score 0 = non diagnostic to 4 = excellent quality), vascular attenuation, signal and contrast to noise ratio (SNR, CNR). Patients were considered evaluable if no segment had a score of 0. RESULTS: Per-patient, the rate of fully evaluable CT scans was 92.1, 95.4 and 94.6 % for iobitridol, iopromide and iomeprol, respectively. Non-inferiority of iobitridol over the best comparator was demonstrated with a 95 % CI of the difference of [-8.8 to 2.1], with a pre-specified non-inferiority margin of -10 %. Although average attenuation increased with higher iodine concentrations, average SNR and CNR did not differ between groups. CONCLUSIONS: With current CT technology, iobitridol 350 mg iodine/ml is not inferior to contrast media with higher iodine concentrations in terms of image quality for coronary stenosis assessment. KEY POINTS: • Iodine concentration is an important parameter for image quality in coronary CTA. • Contrast enhancement must be balanced against the amount of iodine injected. • Iobitridol 350 is non-inferior compared to CM with higher iodine concentrations. • Higher attenuation with higher iodine concentrations, but no SNR or CNR differences.


Asunto(s)
Calcinosis/diagnóstico por imagen , Angiografía por Tomografía Computarizada/métodos , Angiografía Coronaria/métodos , Estenosis Coronaria/diagnóstico por imagen , Adulto , Anciano , Medios de Contraste , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Método Doble Ciego , Femenino , Humanos , Yodo , Yohexol/análogos & derivados , Yopamidol/análogos & derivados , Masculino , Persona de Mediana Edad , Tomografía Computarizada Multidetector/métodos , Tomografía Computarizada por Rayos X/métodos
5.
Autoimmun Rev ; 14(9): 774-80, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25960167

RESUMEN

OBJECTIVE: To determine the diagnostic and prognostic significance of cardiac magnetic resonance imaging (CMRI) in a cohort of patients with eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: We conducted a monocentric retrospective study including 42 EGPA patients who had consecutively undergone CMRI at diagnosis or during follow-up, independently of signs of cardiac involvement. RESULTS: Forty-two patients (male 59.5%, mean age at diagnosis 46.5 years) were included. ANCA was positive in 26.2%, and median EGPA duration before the 1st CMRI screening was 5 months. Seventeen (40.5%) were diagnosed with cardiomyopathy, independently of CMRI findings. CMRI showed myocardial late gadolinium enhancement (LGE) in 82.4% patients with cardiomyopathy vs. 44% without cardiomyopathy (P=0.024). Using LGE as the sole criterion, CMRI sensitivity and specificity for diagnosing cardiomyopathy were 82.4% and 56%, respectively. Among the 15 patients with cardiomyopathy who underwent additional CMRI during follow-up, CMRI-detected cardiac lesions had improved in 7 patients, while those of 8 patients worsened or stabilized despite treatment. These latter patients presented with significantly more cardiac events during follow-up (P=0.026). No differences were found between non-cardiomyopathic patients with or without CMRI anomalies concerning EGPA cardiac manifestations and outcomes. CONCLUSION: The diagnostic significance of myocardial LGE in EGPA patients remains uncertain and should not be the only criterion for cardiomyopathy diagnosis. For patients with no other signs of cardiomyopathy, CMRI-detected anomalies do not seem to adversely affect prognosis or outcome. For patients with cardiomyopathy, CMRI reassessment seems promising in detecting patients with a less favorable cardiac outcome.


Asunto(s)
Granulomatosis con Poliangitis/patología , Miocardio/patología , Eosinófilos , Humanos , Imagen por Resonancia Magnética/métodos , Pronóstico , Estudios Retrospectivos
6.
Int J Endocrinol ; 2015: 213875, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25722719

RESUMEN

The purpose of this paper was to study the value of 18-FDG PET/CT and reassess the value of CT for the characterization of indeterminate adrenal masses. 66 patients with 67 indeterminate adrenal masses were included in our study. CT/MRI images and 18F-FDG PET/CT data were evaluated blindly for tumor morphology, enhancement features, apparent diffusion coefficient values, maximum standardized uptake values, and adrenal-to-liver maxSUV ratio. The study population comprised pathologically confirmed 16 adenomas, 19 metastases, and 32 adrenocortical carcinomas. Macroscopic fat was observed in 62.5% of the atypical adenomas at CT but not in malignant masses. On 18F-FDG PET/CT, SUVmax and adrenal-to-liver maxSUV ratio were significantly lower in adenomas than in malignant tumors. An SUVmax value of less than 3.7 or an adrenal-to-liver maxSUV ratio of less than 1.29 is highly predictive of benignity.

7.
J Vasc Access ; 16(3): 245-9, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25656251

RESUMEN

BACKGROUND: Peripherally inserted central catheters (PICCs) are increasingly used in patients with cystic fibrosis (CF) or with non-CF bronchiectasis, but little data exist on catheter-related complications in this setting. METHODS: Prospective follow-up of consecutive PICCs inserted for intravenous (IV) antibiotics in adults with CF or with non-CF bronchiectasis at Cochin Hospital (Paris, France). RESULTS: Between March 2009 and December 2011, 182 PICCs were prescribed in 117 adults (67 CF and 50 non-CF patients). Ultrasound-guided placement of catheter was successful in 174/182 (95.6%) procedures; no insertion complication occurred. The mean ± SD catheter dwell time was 15 ± 9 days. No catheter-associated bloodstream infection occurred; main complications were symptomatic upper limb deep vein thrombosis (2%), catheter obstruction (18%) and persistent pain after catheter insertion (18%). Patients' satisfaction was high and PICC could be used to perform antibiotic courses in most patients. CONCLUSIONS: PICCs were generally safe for performing IV antibiotic courses in patients with CF or non-CF bronchiectasis, but prolonged pain and/or catheter obstruction occurred in approximately 20% of cases.


Asunto(s)
Antibacterianos/administración & dosificación , Bronquiectasia/tratamiento farmacológico , Cateterismo Venoso Central/efectos adversos , Cateterismo Venoso Central/instrumentación , Cateterismo Periférico/efectos adversos , Cateterismo Periférico/instrumentación , Catéteres de Permanencia , Catéteres Venosos Centrales , Fibrosis Quística/tratamiento farmacológico , Administración Intravenosa , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Bronquiectasia/diagnóstico , Bronquiectasia/microbiología , Obstrucción del Catéter/etiología , Cateterismo Venoso Central/métodos , Cateterismo Periférico/métodos , Fibrosis Quística/diagnóstico , Fibrosis Quística/microbiología , Diseño de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dolor/etiología , Paris , Estudios Prospectivos , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento , Ultrasonografía Intervencional , Adulto Joven
8.
Presse Med ; 43(10 Pt 2): e345-63, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25027464

RESUMEN

Systemic sclerosis per se should not be considered as an a priori contraindication for a pre-transplantation assessment in patients with advanced interstitial lung disease and/or pulmonary hypertension. For lung or heart-lung transplantation, a multidisciplinary approach, adapting the pre-transplant assessment to systemic sclerosis and optimizing systemic sclerosis patient management before, during and after surgery should improved the short- and long-term prognosis. Indications and contraindications for transplantation have to be adapted to the specificities of systemic sclerosis. A special focus on the digestive tract involvement and its thorough evaluation are mandatory before transplantation in systemic sclerosis. As the esophagus is almost always involved, isolated gastro-oesophageal reflux disease, pH metry and/or manometry abnormalities should not be a systematic per se contraindication for pre-transplantation assessment. Corticosteroids may be harmful in systemic sclerosis as they are associated with acute renal crisis. A low dose corticosteroids protocol for immunosuppression is therefore advisable in systemic sclerosis.


Asunto(s)
Trasplante de Corazón-Pulmón , Esclerodermia Sistémica/cirugía , Cardiopatías/etiología , Cardiopatías/cirugía , Humanos , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/cirugía , Persona de Mediana Edad , Estudios Retrospectivos , Esclerodermia Sistémica/complicaciones
9.
Int J Cardiovasc Imaging ; 30(5): 959-60, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24715438

RESUMEN

We report a case of severe mitral stenosis caused by Libman-Sacks endocarditis, as an initial manifestation of systemic lupus erythematosus (SLE) in a 20-year-old woman. Cardiac magnetic resonance imaging (MRI) demonstrated a thickening of the mitral valve with basal endocardial thickening exhibiting defect on first-pass perfusion short-axis acquisition and delayed enhancement in keeping with extensive fibrous endocarditis. The patient underwent successful mechanical mitral valve replacement. This case illustrates that MRI is useful in diagnosing this recognised but uncommon cardiac complication of SLE and excluding differential diagnosis such as valve tumour and infective endocarditis with perivalvular abscesses.


Asunto(s)
Endocarditis/diagnóstico , Endocarditis/etiología , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/diagnóstico , Imagen por Resonancia Cinemagnética/métodos , Estenosis de la Válvula Mitral/diagnóstico , Estenosis de la Válvula Mitral/etiología , Diagnóstico Diferencial , Endocarditis/cirugía , Femenino , Prótesis Valvulares Cardíacas , Implantación de Prótesis de Válvulas Cardíacas , Humanos , Estenosis de la Válvula Mitral/cirugía , Adulto Joven
11.
Rheumatology (Oxford) ; 52(4): 642-50, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22772324

RESUMEN

OBJECTIVE: Churg-Strauss syndrome (CSS) cardiac involvement is associated with a poor prognosis. Recently cardiac MRI (CMRI) has emerged as a promising technique to detect early CSS cardiac involvement. However, CMRI-detected myocardial delayed enhancement (MDE) could correspond to fibrosis or inflammation. Fluoro-2-deoxyglucose PET (FDG-PET) was previously used in other systemic diseases to distinguish between them. To determine whether the CMRI-MDE detected in CSS patients reflected fibrosis or myocardial inflammation, patients in CSS remission underwent FDG-PET. METHODS: Twenty consecutive CSS patients in remission (BVAS = 0) were recruited. Fourteen patients [eight men, six women; mean (S.D.) age 49 (9) years; mean disease duration 3.5 (2.9) years] with CMRI-detected MDE, and six patients [four men, two women; mean (S.D.) age 44 (15) years; mean disease duration 3.5 (5.3) years] with normal CMRI underwent FDG-PET. Segments with MDE on CMRI were analysed on FDG-PET images, with myocardial FDG hypofixation defining fibrosis and hyperfixation corresponding inflammation. RESULTS: Among the 14 patients with MDE on CMRI, FDG-PET showed 10 had hypofixation, 2 had hyperfixation and 2 had normal scans. CSS duration at the time of CMRI was shorter for patients with myocardial inflammation than in those with fibrosis. The six patients with normal CMRI had normal FDG-PET images. CONCLUSION: For CSS patients in remission, CMRI detected subclinical active myocardial lesions and could be recommended to assess cardiac involvement. However, because CMRI-detected MDE can reflect fibrosis or inflammation, FDG-PET might help to distinguish between the two.


Asunto(s)
Síndrome de Churg-Strauss/diagnóstico , Cardiopatías/diagnóstico , Imagen por Resonancia Magnética/métodos , Tomografía de Emisión de Positrones/métodos , Adulto , Síndrome de Churg-Strauss/terapia , Diagnóstico Diferencial , Femenino , Fibrosis , Fluorodesoxiglucosa F18 , Humanos , Masculino , Persona de Mediana Edad , Miocarditis/diagnóstico , Miocardio/patología , Estudios Prospectivos , Radiofármacos , Inducción de Remisión
12.
AJR Am J Roentgenol ; 198(1): 98-105, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22194484

RESUMEN

OBJECTIVE: The purpose of this study is to describe an imaging method based on a CT technique, CT antegrade colonography, for the evaluation of low anastomosis and to evaluate the value of CT antegrade colonography before early ileostomy closure after proctectomy in low rectal endometriosis. MATERIALS AND METHODS: One hundred ninety-five patients referred for low rectal endometriosis underwent proctectomy and were eligible for early ileostomy closure. All patients underwent standard antegrade fluoroscopy (n=77) or CT antegrade colonography (n=118) 8 days after surgery. The negative predictive values, positive predictive values, sensitivity, specificity, and likelihood ratio of standard antegrade fluoroscopy and CT antegrade colonography in detecting anastomotic leakage and abscesses were assessed. The reference standard for positive and negative examinations was based on clinical follow-up, imaging, surgical, or interventional procedure findings. RESULTS: Negative and positive predictive values for detecting anastomotic leakage were 100% (95% CI, 96.8-100%) and 100% (95% CI, 39.8-100%), respectively, for CT antegrade colonography and 98.6% (95% CI, 92.4-100%) and 100% (95% CI, 54.1-100%), respectively, for standard antegrade fluoroscopy. The negative and positive predictive values for detecting abscess were 100% (95% CI, 96.8-100%) and 100% (95% CI, 47.8-100%), respectively, for CT antegrade colonography and 97.3% (95% CI, 90.8-99.7%) and 100% (95% CI, 2.5-100%), respectively, for standard antegrade fluoroscopy. CONCLUSION: CT antegrade colonography may play a major role in the evaluation of low anastomosis protected by an ileostomy after proctectomy in low rectal endometriosis, leading to the development of a new strategy with early restoration of the intestinal continuity.


Asunto(s)
Colonografía Tomográfica Computarizada/métodos , Endometriosis/diagnóstico por imagen , Endometriosis/cirugía , Complicaciones Posoperatorias/diagnóstico por imagen , Proctocolectomía Restauradora/métodos , Enfermedades del Recto/diagnóstico por imagen , Enfermedades del Recto/cirugía , Absceso/diagnóstico por imagen , Adulto , Fuga Anastomótica/diagnóstico por imagen , Distribución de Chi-Cuadrado , Medios de Contraste , Diatrizoato , Femenino , Fluoroscopía , Humanos , Ileostomía , Funciones de Verosimilitud , Valor Predictivo de las Pruebas , Interpretación de Imagen Radiográfica Asistida por Computador , Estudios Retrospectivos , Sensibilidad y Especificidad
13.
PLoS One ; 6(2): e16978, 2011 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-21340026

RESUMEN

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.


Asunto(s)
Bencenosulfonatos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Hipertensión Portal/fisiopatología , Cirrosis Hepática/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Vena Porta/efectos de los fármacos , Piridinas/uso terapéutico , Flujo Sanguíneo Regional/efectos de los fármacos , Adulto , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Bencenosulfonatos/efectos adversos , Carcinoma Hepatocelular/complicaciones , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/patología , Progresión de la Enfermedad , Femenino , Humanos , Hipertensión Portal/tratamiento farmacológico , Hipertensión Portal/etiología , Cirrosis Hepática/complicaciones , Cirrosis Hepática/fisiopatología , Neoplasias Hepáticas/complicaciones , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Angiografía por Resonancia Magnética , Masculino , Persona de Mediana Edad , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Vena Porta/fisiología , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridinas/efectos adversos , Sorafenib , Análisis de Supervivencia
14.
Invest New Drugs ; 29(5): 1090-3, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20524036

RESUMEN

Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.


Asunto(s)
Bencenosulfonatos/efectos adversos , Indoles/efectos adversos , Neoplasias/tratamiento farmacológico , Neumatosis Cistoide Intestinal/inducido químicamente , Inhibidores de Proteínas Quinasas/efectos adversos , Piridinas/efectos adversos , Pirroles/efectos adversos , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Adulto , Bencenosulfonatos/sangre , Bencenosulfonatos/uso terapéutico , Progresión de la Enfermedad , Resultado Fatal , Femenino , Humanos , Indoles/sangre , Indoles/uso terapéutico , Masculino , Persona de Mediana Edad , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Neumatosis Cistoide Intestinal/diagnóstico por imagen , Inhibidores de Proteínas Quinasas/sangre , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridinas/sangre , Piridinas/uso terapéutico , Pirroles/sangre , Pirroles/uso terapéutico , Radiografía , Sorafenib , Sunitinib , Factor A de Crecimiento Endotelial Vascular/metabolismo
15.
Invest New Drugs ; 29(6): 1497-9, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20676744

RESUMEN

Patients treated with anti-VEGF agents are at increased risk for arterial thrombo-embolic events (ATEs). However, the pathophysiology of such acute vascular complications remains unclear. We report on a case of bowel infarction in a renal cancer patient treated with the anti-VEGF agent sunitinib. An abdominal CT-scan evidenced the rupture of an atherosclerotic plaque located at the emergence of the superior mesenteric artery. In view of this report, we suggest that evaluation of the risk of ATE in patients receiving anti-VEGF agents should include not only age and past history of ATE as suggested by previous studies, but also assessment of atherosclerotic lesions on CT-scan.


Asunto(s)
Antineoplásicos/efectos adversos , Indoles/efectos adversos , Placa Aterosclerótica/patología , Pirroles/efectos adversos , Tromboembolia/etiología , Anciano , Inhibidores de la Angiogénesis/efectos adversos , Inhibidores de la Angiogénesis/farmacología , Inhibidores de la Angiogénesis/uso terapéutico , Antineoplásicos/farmacología , Humanos , Indoles/farmacología , Indoles/uso terapéutico , Infarto/etiología , Intestinos/irrigación sanguínea , Masculino , Pirroles/farmacología , Pirroles/uso terapéutico , Factores de Riesgo , Sunitinib , Tromboembolia/fisiopatología , Tomografía Computarizada por Rayos X , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores
16.
Clin Exp Rheumatol ; 28(1 Suppl 57): 8-13, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20412695

RESUMEN

OBJECTIVES: To evaluate the effects of immunosuppressive therapy on cardiac abnormalities observed by cardiac magnetic resonance imaging (CMRI) in patients with Churg-Strauss syndrome (CSS). METHODS: We studied 8 patients with CSS and myocardial involvement on initial CMR images, who underwent follow-up CMRI after 6 months of immunosuppressive therapy. RESULTS: Among the 8 patients (mean age: 43 years; 4 women), 7 had clinical cardiac signs at CSS onset (cardiac insufficiency, 3; angina pectoris, 2; atrial fibrillation, 1; and pericarditis, 1); 4 of them had myocardial-delayed enhancement, 2 had perfusion defects and 1 had both CMRI anomalies. The patient without clinical manifestations of heart disease had myocardial delayed enhancement on CMRI. After 6 months of therapy, CMR images normalised for the patient without clinical cardiac signs at diagnosis, and 3 symptomatic patients, and abnormalities had regressed for 2 other symptomatic patients. Theses 5 initially symptomatic patients became asymptomatic after immunosupressive treatment. The last 2 patients with cardiac insufficiency at CSS diagnosis are still symptomatic with unchanged CMRI abnormalities. CONCLUSIONS: CMRI is a sensitive, non-invasive method to detect cardiac lesions in patients whose conventional investigations indicated no cardiac disease and to assess the extent of cardiac involvement in symptomatic patients. CMRI can help evaluate the therapeutic effect of immunosuppressants in CSS.


Asunto(s)
Síndrome de Churg-Strauss/tratamiento farmacológico , Síndrome de Churg-Strauss/patología , Cardiopatías/tratamiento farmacológico , Cardiopatías/patología , Inmunosupresores/uso terapéutico , Imagen por Resonancia Magnética/métodos , Adulto , Síndrome de Churg-Strauss/inmunología , Monitoreo de Drogas/métodos , Diagnóstico Precoz , Electrocardiografía , Femenino , Estudios de Seguimiento , Cardiopatías/inmunología , Humanos , Masculino , Persona de Mediana Edad , Miocardio/patología , Sensibilidad y Especificidad , Volumen Sistólico/efectos de los fármacos
17.
World J Gastroenterol ; 14(44): 6869-72, 2008 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-19058317

RESUMEN

Most patients with hepatocellular carcinoma (HCC) are not eligible for curative treatment, which is resection or transplantation. Two recent series have emphasized the potential benefits of preoperative arterio-portal embolization prior to surgical resection of such tumours. This preoperative strategy offers a better disease free survival rate and a higher rate of total tumor necrosis. In case of non resectable HCC it is now widely accepted that transarterial chemoembolization (TACE) leads to a better survival when compared to conservative treatment. Thus, the question remains whether combined portal vein embolization (PVE) may enhance the proven efficiency of TACE in patients with unresectable HCC. We herein report the case of a 56-year-old cirrhotic woman with a voluminous HCC unsuitable for surgical resection. Yet, complete tumour necrosis and prolonged survival could be achieved after a combined porto-arterial embolization. This case emphasizes the potential synergistic effect of a combined arterio-portal embolization and the hypothetical survival benefit of such a procedure, in selected patients, with HCC not suitable for surgery or local ablative therapy.


Asunto(s)
Carcinoma Hepatocelular/terapia , Embolización Terapéutica , Cirrosis Hepática Alcohólica/complicaciones , Neoplasias Hepáticas/terapia , Neoplasias Óseas/secundario , Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/etiología , Resultado Fatal , Femenino , Hepatectomía , Humanos , Cirrosis Hepática Alcohólica/diagnóstico por imagen , Cirrosis Hepática Alcohólica/terapia , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/etiología , Persona de Mediana Edad , Necrosis , Recurrencia Local de Neoplasia , Portografía , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
18.
Surg Today ; 38(6): 572-5, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18516543

RESUMEN

Pyogenic liver abscess is an unusual cause of fever and abdominal pain, but it is potentially fatal. It is rarely caused by a local event, but rather by hematogenous dissemination or biliary tract disease. We report an uncommon case of liver abscess caused by the migration of a fish bone through the gastrointestinal wall.


Asunto(s)
Migración de Cuerpo Extraño/complicaciones , Absceso Hepático/etiología , Animales , Huesos , Peces , Migración de Cuerpo Extraño/diagnóstico por imagen , Humanos , Absceso Hepático/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Recurrencia , Tomografía Computarizada por Rayos X , Ultrasonografía
19.
Presse Med ; 37(3 Pt 1): 412-5, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18276102

RESUMEN

INTRODUCTION: Cardiac involvement is a rare manifestation of Wegener granulomatosis (WG). Because its prognosis can be poor, it must be diagnosed early to be treated adequately. We report the disease course of a patient who received rituximab to treat cardiac involvement documented by contrast-enhanced cardiac magnetic resonance imaging (ceCMR). CASE: This WG patient developed myocarditis with atrioventricular block. CeCMR proved useful in the diagnosis and follow-up of cardiac involvement. Several unsuccessful regimens preceded the prescription of rituximab. Two months later, regression of the myocarditis shown by ceCMR images was correlated with electrophysiological improvement. DISCUSSION: CeCMR assessment of a heart conduction defect in a patient with WG showed that this tool was useful for the diagnosis and follow-up of cardiac involvement in this vasculitis. Rituximab was an effective treatment in this patient.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Bloqueo Atrioventricular/tratamiento farmacológico , Granulomatosis con Poliangitis/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Miocarditis/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales de Origen Murino , Bloqueo Atrioventricular/etiología , Bloqueo Atrioventricular/patología , Granulomatosis con Poliangitis/complicaciones , Humanos , Imagen por Resonancia Cinemagnética , Masculino , Miocarditis/etiología , Miocarditis/patología , Rituximab
20.
Presse Med ; 36(5 Pt 2): 913-21, 2007 May.
Artículo en Francés | MEDLINE | ID: mdl-17383849

RESUMEN

Sinonasal CT must be studied with both soft tissue and bone algorithms. Sinonasal findings in Wegener's granulomatosis are mucosal thickening, subtotal opacification, air-fluid level, bony destruction (mainly of the nasal septum), and sclerosing osteitis. Orbital MRI helps to define the extent of the disease. Contiguous granulomatous infiltration of the orbit appears dark (hypointense signals) on both T2-weighted-and T1-weighted images, but is enhanced after gadolinium administration. Cerebral MRI findings include diffuse linear dural thickening, enhanced by injection, and local dural thickening contiguous with orbital, nasal and paranasal disease. The remote granulomatous lesions in brain parenchyma are the least common form of central nervous system lesion. The pituitary gland and infundibulum can also be involved in Wegener's granulomatosis. These imaging findings of Wegener's granulomatosis are nonspecific. They should be combined with clinical examination and c-ANCA tests to confirm the diagnosis.


Asunto(s)
Encéfalo/patología , Granulomatosis con Poliangitis/diagnóstico por imagen , Granulomatosis con Poliangitis/diagnóstico , Imagen por Resonancia Magnética , Meninges/patología , Tabique Nasal/diagnóstico por imagen , Órbita/diagnóstico por imagen , Órbita/patología , Senos Paranasales/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Adulto , Algoritmos , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Biomarcadores , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Seno Maxilar/diagnóstico por imagen , Persona de Mediana Edad , Hipófisis/patología , Pronóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA